TG Therapeutics Presents Preclinical Data for TG-1801, a First-in-Class Anti-CD47/CD19 Bispecific Antibody, at the 24th European Hematology Association Annual Congress

June 17, 2019

We're not around right now. But you can send us an email and we'll get back to you, asap.

Start typing and press Enter to search